

RADIOPHARMACEUTICAL PRODUCTS AND  
THEIR PREPARATION PROCEDURE

Technical field

The present invention relates to radiopharmaceutical products which can be used for diagnosis or therapy and to their preparation procedure.

In particular, it relates to radiopharmaceutical products formed for example from a suspension of particles labelled by a radioactive isotope utilisable in particular for pulmonary scintigraphy, for example in order to establish a diagnosis when a pulmonary embolism is suspected.

In this application, the products are used under the form of particles which are preferably spherical in shape and of a size ranging from 10 to 100 $\mu$ m. In fact, since the pulmonary capillaries have a diameter of about 7 $\mu$ m, the particles remain blocked in the capillaries after their intravenous injection, which makes it possible to visualise anomalies of pulmonary blood perfusion.

Evidently these products must fulfil a certain number of pharmaceutical restrictions. In particular they must have a suitable degradation rate in vivo, that is sufficiently slow to allow imagery to be carried out, for example by a gamma-ray camera, a minimum of about one hour, but also sufficiently rapid so as not to provoke permanent obstruction of the pulmonary capillaries, which could give rise to small thromboses. In addition, these products must not be



toxic for the organism, they must be able to be  
 sterilised for example by autoclaving or by  
 irradiation, they must be able to be labelled easily  
 with a radioactive metal and be able to be packaged  
 5 under the form of a stable labelling kit.

Prior Art

For example, the application for French brevet FR-A-2 273  
 516 (equivalent to GB 1 518 813), deposited in 1975 by the  
 PHARMACIA AKTIEBOLAG Company, resident in Sweden, describes  
 10 the use of microspheres of amylopectin reticulated by  
 epichlorhydrin and labelled by a simple mixture with  
<sup>99m</sup>Tc for pulmonary perfusion scintigraphy. These  
 particles present several inconveniences. In fact, only  
 the hydroxyl groupings of ~~amylopectin~~ <sup>amylopectin</sup> used can allow  
 15 this mixture labelling, and unfortunately they only  
 form weak bonds with technetium and do not make stable  
 labelling possible. In addition, the preparation  
 procedure described uses many solvents and emulsifiers  
 which are difficult to eliminate from the particles  
 20 prepared. Furthermore, the exact rate of reticulation  
 cannot be measured accurately nor controlled on this  
 particle type.

Moreover, this document does not describe the kit  
 compatible with routine utilisation in nuclear  
 25 medicine. In fact, for an injectable preparation for  
 humans, several manipulations such as adjunction of tin  
 to the sterile flask, a centrifuging, a restoration of  
 suspension, etc. are necessary, which is not compatible  
 with sterility requirements.



Finally, the solutions obtained are not stable and the epichlorhydrin used for reticulation is recognised as being very toxic and mutagenic.

The inventors demonstrated other defects of these  
5 microparticles in the comparative examples 1 and 2 below.

The application for French brevet FR-A-2 285 857\* deposited in 1975 by the PHARMAGIA FINE CHEMICALS AB Company, resident in Sweden, describes the utilisation  
10 of polysaccharide particles linked to different sequestering agents and labelled with the aid of radioactive isotopes. The particles comprise chelating groups linked by covalent bonds to which the radioactive nucleus is linked under the form of chelate  
15 type complexes which are principally composed of at least four, and preferably at least five to eight cyclic nuclei with 5 to 6 groups, enclosing the metal, and two metal-coordinating atoms. The polysaccharide is a polysaccharide reticulated chemically, for example by  
20 means of epichlorhydrin or epibromhydrin. Leaving the labelling aside, these particles present the same problems as those mentioned previously for the particles described in FR-A-2 273 516 (equivalent to GB 1 518 813). Moreover, this document does not give any examples  
25 of labelling with technetium. Further, the labelling procedure comprises heating to 100°C in the presence of the radioactive element, a washing and a drying after labelling, which is not at all compatible with the idea of the above-mentioned labelling kit and the restrictions of  
30 sterility of usage.

\* available on request

Even though the labelling method described allows the particles to be labelled in a relatively stable manner, it does not make it possible to prepare a labelling kit which is pharmaceutically acceptable, in particular because it contains epichlorhydrin, and easily usable in a nuclear medicine service.

The microspheres described in these two brevet applications are thus not adapted to the pharmaceutical restrictions and they cannot be exploited. Moreover they have never been used for pulmonary scintigraphy. This type of product has been abandoned since.

The many researches carried out since 1975 for perfecting new radiopharmaceutical products have concentrated on products based on albumin-serum and its derivatives. These blood products do in fact correspond to pharmaceutical restrictions and can be used in particular for pulmonary scintigraphy. These are the products used at present in nuclear medicine.

For example, in 1975, M.A. Davis, in the document "Radiopharmaceuticals N.Y.", 1975, pages 267 to 281, described the radioactive particles intended for the study of pulmonary perfusion. The particles described in this document are macro-aggregates of radio-iodinated serum albumin ( $^{131}\text{I}$ -MAA) or microspheres of denatured human serum albumin labelled with technetium ( $^{99\text{m}}\text{Tc}$ -HAM). The microspheres of  $^{99\text{m}}\text{Tc}$ -HAM are preferable, because of their uniformity of particle size ranging essentially between 40 and 50  $\mu\text{m}$ . Moreover this document describes the general characteristics required for such radiopharmaceutical particles.

The document of R. Guiraud "Macro-aggregates and radioactive microspheres", Radiopharmaceuticals, 1997, 519, describes macro-aggregates of albumin (MAA) and microspheres of human serum albumin. It describes the labelling of such micro-aggregates and microparticles with technetium 99m by a solution of stannous chloride. It also notes that the optimum size for the microparticles is  $15 \pm 5 \mu\text{m}$ . It mentions organic microspheres of starch.

At present, these macro-aggregates and microspheres of human serum albumin labelled with  $^{99\text{m}}\text{Tc}$  are by far the most utilised in nuclear medicine. However, they present several inconveniences. For example, the variability and quality of batches of human albumin sometimes make preparation of diagnosis kits difficult, containing particles which can vary in size and number. But one of the major inconveniences is their human origin, which can pose serious problems of potential vital contamination of the type HIV, hepatitis, or Creutzfeld-Jacob disease.

It would therefore be very interesting to be able to have microspheres labelled with  $^{99\text{m}}\text{Tc}$  which are not of human origin in order to ensure perfect safety.

With this in view, the very recent document of A.C. Perkins, Nuclear Medicine Communications, 1999, 20, 1-3 describes ways of replacing radiopharmaceutical products obtained from blood. In particular it mentions the utilisation of recombinant materials, synthetic polymers and polypeptides. But, this document does not mention polysaccharides.

Description of the invention

The precise aim of the invention is to overcome the inconveniences mentioned above for prior art products, by providing a radiopharmaceutical product  
 5 being able to be easily labelled, for example with  $^{99m}\text{Tc}$ , presenting a very good pulmonary captation which has been demonstrated by inventors for rats, non-toxic, easily biodegradable, easily sterilisable and able to be packaged as a kit ready for labelling, stable and  
 10 fulfilling the pharmaceutical restrictions for this type of product. These advantages and others will be evident from the following description.

The radiopharmaceutical product of the present invention is characterised in that it comprises a  
 15 polysaccharide provided with sequestering agents linked to the polysaccharide by covalent bonds and chosen among the groups of formulae  $\text{R-NH-}$ ,  $\text{R-N=}$ , and



in which R is a hydrocarbonic or aromatic group  
 20 comprising at least one atom of sulphur, and R' is a hydrogen atom or an alkyl grouping, for example methyl, said sequestering groups forming a chelate type complex with a radioactive metal chosen from among technetium, rhenium, copper, yttrium, erbium, gallium and samarium.

25 The utilisable alkyl groups for R' can be linear or branched, and preferably they have 1 to 5 carbon atoms.

According to the invention, the polysaccharide can be soluble, or in the form of microparticles. According


to the invention, the polysaccharide can be chosen, for example, from among natural starch, cellulose or reticulated amylopectin.

The natural <sup>amylopectin</sup> starch can, for example, be maize starch.

The polysaccharide can be in the form of microparticles, for example in the form of microspheres.

The present inventors have also demonstrated that modified cellulose according to the present invention offers very good pulmonary captation and an elimination speed slower than with starch. The modified cellulose of the present invention can therefore also be used for radiotherapy, for example with labelling with rhenium, copper, or with one of the above-mentioned metals, since it corresponds to the radiotherapy necessity of using microparticles with a longer half-life.

According to the invention, the sequestering groups can be chosen for example from the groups with formulae:



IPONZ


- 2 JUL 2003

in which  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are independently hydrogen atoms, saturated or unsaturated hydrocarbonic groups, carboxylic groups or aromatic groups,

(A)

is an aromatic nucleus possibly containing one or several hetero-atoms, and  $n$  is a whole number between 1 and 5.


For example, they can be chosen from among the formula groups:



10

IPONZ  
- 2 JUL 2003





According to the invention, the microparticles, for example in the shape of microspheres, can be of a dimension from 0.01 to 100  $\mu\text{m}$ , preferably from 10 to 50  $\mu\text{m}$  for diagnosis by pulmonary scintigraphy and from 0.1 to 5  $\mu\text{m}$  for therapy.

According to the invention, the levels of sequestering groups can be from 0.1 to 50% compared to the saccharide units of the polysaccharide, preferably from 2 to 15%.

According to the invention, in the radiopharmaceutical product, particularly when it is

**IPONZ**

- 2 JUL 2003

used for diagnosis, the radioactive metal can be  $^{99m}\text{Tc}$  or gallium-67.


This can be the case, for example, when the radiopharmaceutical product is used for pulmonary  
5 scintigraphy.

According to the invention, in the radiopharmaceutical product, in particular when it is used for therapy, the radioactive metal can be rhenium-186 or 188, copper-64 or 67, yttrium-90, erbium-169 or  
10 samarium-153.

According to the invention, said radiopharmaceutical product can be in the form of a suspension of microspheres in a physiologically acceptable liquid or in lyophilised form.

15 The present invention also provides a preparation procedure for the radiopharmaceutical product of the invention comprising the following stages:

- (a) submit a polysaccharide, for example such as those mentioned above, to oxidation controlled by means of  
20 a periodate,  
(b) react the oxidised polysaccharide with a compound containing a primary amine function or hydrazin of formula  $\text{R-NH}_2$  or



- 25 (c) in which R is a hydrocarbonic or aromatic group comprising at least one atom of sulphur, in order to bond in a covalent manner to the polysaccharide with sequestering groups the metals of formulae  $\text{R-NH-}$ ,  $\text{R-}$


N= or R-NH-N=, and R' is a hydrogen atom or an alkyl grouping, for example methyl.

- (d) react the polysaccharide comprising the sequestering groups with a salt of a radioactive metal chosen from among technetium, rhenium, copper, yttrium, erbium and samarium.

The oxidation controlled by means of a periodate can be that described, for example, in C.L. Mehlretter, "Methods in Carbohydrate Chemistry", vol. IV, 1964, applied in particular to the oxidation of starch, dextrane or cellulose. It is used in the examples given below.

According to the invention, the compound containing a primary amine function can correspond to the formula  $\text{NH}_2-(\text{CH}_2)_n-\text{SH}$  with n being a whole number between 1 and 5, and can include a supplementary reducing stage of this compound with sodium borohydride between stages (b) and (c).

According to the invention, the compound bonded to the polysaccharide can correspond, for example, to one of the following formulae:




According to the invention, the level of sequestering groups fixed on the polysaccharide can be regulated by controlling the level of oxidation of the polysaccharide in stage (a) mentioned above. This oxidation level of polysaccharide can, for example, be between 10 to 50%. The level of the sequestering group can, for example, be between 2 and 15%.

10 In order to allow labelling of the polysaccharide according to the invention, for example with  $^{99\text{m}}\text{Tc}$ , the inventors have therefore used a two-stage transformation method.

15 This method can be presented as consisting of carrying out a controlled oxidation of the

polysaccharide by the periodate in the first stage. Each unit of oxidised glucose thus generates two aldehyde groups in neighbouring positions following the chemical reaction diagram given below:




5 natural glucoside monomer

oxidised glucoside monomer

The level of oxidation of the polysaccharide can be variable and easily adjusted. In fact, the yield of this oxidation reaction is close to 100% and the level of oxidation can be calculated from the quantities of periodate added. In general, oxidation levels lower than 50% are used so as to modify the structure of the macromolecule only slightly. The real oxidation level, ranging from 1 to 100%, can easily be determined by a colorometric method.

In the second stage, the oxidised polysaccharide is made to react with a molecule containing an amine or hydrazin grouping with the general formula  $\text{RNH}_2$  or  $\text{RNHNH}_2$  to form a chelating grouping able to sequester technetium. Thus one obtains a Schiff base type ligand or thiosemicarbazone.

This second stage can be summarised as follows:



with:

1.  $\text{R} = \text{NR}_1(\text{C}=\text{S})\text{SR}_2$  (Schiff bases issued from  
5 dithiocarbazate)
2.  $\text{R} = \text{NR}_1(\text{C}=\text{S})\text{NR}_2\text{R}_3$  (thiosemicarbazones)
3.  $\text{R} =$  aromatic grouping (aromatic Schiff bases)
4.  $\text{R} =$  alkyl grouping (alkylic Schiff bases); in this  
10 case the Schiff bases are not stable and one carries  
out a second reduction stage of the  $\text{C}=\text{N}$  bond with  
borohydride so as to stabilise it and then an amine  
 $\text{C}-\text{NHR}$  bond is obtained.

According to the invention, stage (c) can for  
example consist of putting into contact the  
15 microspheres of polysaccharide comprising the  
sequestering groups for example with a solution of  
pertechnetate  $^{99\text{m}}\text{TcO}_4^-$  in the presence of a reducing  
agent, for example stannous chloride.

According to the invention, microparticles, for  
20 example microspheres, for example maize starch or

23-10-01:10112

DESC

0005-1733-1B000

starch with a base of reticulated ~~amylopectin~~ <sup>amylopectin</sup> can thus be oxidised, then coupled to a molecule containing an amine or hydrazin function, for example S-methyl dithiocarbazate. These particles modified in this way  
5 can easily be labelled with, for example, <sup>99m</sup>Tc.

The present invention thus provides in particular microparticles prepared for example from a base of starch particles, which therefore do not present the inconveniences of the albumin mentioned above. In  
10 addition, the starch is described as an excipient in the pharmacopoeia. It is therefore easily available and at low cost.

The microparticles of the present invention also have the advantage of being able to be sterilised  
15 easily, for example by irradiation, and to be processed under the form of a kit ready for labelling.


Moreover, the present inventors have demonstrated according to the present invention that the speed of pulmonary clearance can be modified according to the  
20 level of oxidation of the microparticles used in the present invention, which is not possible, for example, with human albumin microspheres.

Another advantage of the present invention lies in the simplicity of operation of the procedure: the  
25 reaction conditions being very gentle: reactions at ambient temperature, in an aqueous medium, quasi-quantitative yields. In addition, the sequestering reactions, for example with technetium, are quantitative; they take place at room temperature and  
30 without final purification which makes it possible to adapt to the requirements of sterility and simplicity

of preparation necessary for the utilisation of technetised kits in the hospital environment.

The present invention also provides a diagnosis kit which can be used, for example, for pulmonary  
5 scintigraphy. This kit comprises:

a first flask containing a polysaccharide according to the invention, that is to say provided with sequestering groups linked to the polysaccharide by covalent bonds and chosen among  
10 the groups of formulae R-NH-, R-N= and



in which R is a hydrocarbonic or aromatic group comprising at least one atom of sulphur, and in which R' is a hydrogen atom or an alkyl grouping  
15 such as methyl.

According to the invention, the polysaccharide can, for example, be in the form of microparticles, for example in the shape of microspheres, the microparticles being able to be in lyophilised form or  
20 in suspension in a pharmaceutically acceptable liquid.

The kit of the present invention can furthermore comprise a second flask containing stannous chloride preferably in lyophilised form, or also when the polysaccharide is in lyophilised form, for example in  
25 the form of microparticles, in the first flask, said first flask can besides contain lyophilised stannous chloride.



The kits of the present invention are stable for at least twelve months as demonstrated in the examples given below.

The radiopharmaceutical product of the present invention therefore presents all the qualities required for a use such as radiopharmaceutical usage, for example for scintigraphy of pulmonary perfusion or for radiotherapy.

Other advantages will also appear when reading the following examples related to the present invention.

#### EXAMPLES

##### Example 1

A suspension of 10 g of maize starch from the pharmacopoeia is prepared, previously sieved between 10 and 40  $\mu\text{m}$ , containing about 10% water, that is 0.055 mole of glucose in 100 ml of water. One adds 0.0168 mole of sodium periodate (0.3 eq) ( $\text{NaIO}_4$ ), that is 3.6 g, dissolved in 100 ml of water. The suspension is then stirred for 18 hours at room temperature. The solution is filtered and the oxidised starch is rinsed by 5 times 20 ml of water and then 2 times 50 ml of acetone. The starch is vacuum dried and one obtains 10 g of starch oxidised at 30% (yield = 100%).

A suspension of 10 g of starch oxidised at 30% is prepared in 60 ml of a water/ethanol mixture 2/1 by volume. Next one adds 0.1 eq ( $0.1 \times 0.055 \times 2$ ) that is 0.011 mole of S-methyl dithiocarbazate ( $\text{NH}_2\text{NH}(\text{C}=\text{S})\text{SCH}_3$ ),  $M=122$ , that is 1.34 g, dissolved in 10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. The solution is next filtered and the

modified starch is washed by 3 times 20 ml of ethanol and then vacuum dried. One thus obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 5.4%, which  
5 corresponds to a coupling level of S-methyl dithiocarbazate (DTCZ) of 7% (7 units dithiocarbazate for 100 theoretical aldehyde functions that is 14 dithiocarbazate units for 100 glucose units). The coupling yield is therefore 70%. One thus obtains 10 g  
10 of starch oxidised at 30% and coupled to the DTCZ at 7%.

Labelling reaction with  $^{99m}\text{Tc}$

10 mg of starch thus modified are introduced into a flask of the penicillin type. One then adds 4 ml of  
15 physiological serum then 10  $\mu\text{g}$  of  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  (20  $\mu\text{l}$  of a solution at 0.5 mg/ml in  $\text{HCl}$  0.1 N). Then 1 ml of a solution of  $^{99m}\text{TcO}_4^-$  (5mc) is added. The solution is stirred for 15 minutes and the radiochemical purity control (RCP) is carried out by filtration of 1 ml of  
20 the solution on a Millipore filter of 0.22  $\mu\text{m}$  then the filter is rinsed by 2ml of physiological serum. The labelled microspheres are retained on the filter contrary to the radioactive impurities not linked to the microspheres which are found in the filtrate. The  
25 radiochemical purity corresponds to:

$$\text{RCP} = (\text{activity on the filter} / \text{total activity}) \times 100$$

It is 98.9%.

**Example 2****Starch modification**

One proceeds as for example 1 but one uses 0.2 eq of periodate during the oxidation reaction. One obtains a starch oxidised at 20%.

- 5 One proceeds in the same way as for example 1 for the coupling reaction and one obtains a starch oxidised at 20% and coupled to the DTCZ at 7%.

**Labelling reaction with  $^{99m}\text{Tc}$** 

- 10 One proceeds as for example 1. The radiochemical purity (RCP) is 99%.

**Example 3****Starch modification**

One proceeds as for example 1 but one uses 0.1 eq of periodate during the oxidation reaction. One obtains a starch oxidised at 10%.

- 15 One proceeds in the same way as for example 1 for the coupling reaction and one obtains a starch oxidised at 10% and coupled to the DTCZ at 7%.

**Labelling reaction with  $^{99m}\text{Tc}$** 

- 20 One proceeds as for example 1. The radiochemical purity (RCP) is 98.8%.

**Example 4**

- 25 One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq ( $0.1 \times 0.055 \times 2$ ), that is 0.011 mole of N-methyl-S-methyl dithiocarbazate ( $\text{NH}_2\text{N}(\text{CH}_3)(\text{C}=\text{S})\text{SCH}_3$ ),  $M=136$ , that is 1.50 g dissolved in 10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. The solution

is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 5%, which corresponds to a coupling level of the N-methyl S-methyl dithiocarbazate of 6.5% (6.5 units dithiocarbazate for 100 theoretical aldehyde functions, that is 13 dithiocarbazate units for 100 units glucose). The coupling yield is thus 65%.

10 Labelling reaction to  $^{99m}\text{Tc}$

One proceeds as for example 1. The RCP is 95%.

Example 5

Starch modification

One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq ( $0.1 \times 0.055 \times 2$ ), that is 0.011 mole of 4-phenyl 3-thiosemicarbazide ( $\text{NH}_2\text{NH}(\text{C}=\text{S})\text{NH}(\text{C}_6\text{H}_5)$ ,  $M=167$ , that is 1.83 g dissolved in 10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 3.16%, which corresponds to a coupling level of the 4-phenyl 3-thiosemicarbazone of 8% (8 units thiosemicarbazide for 100 theoretical aldehyde functions, that is 16 thiosemicarbazone units for 100 units glucose). The coupling yield is thus 80%.

30 Labelling reaction with  $^{99m}\text{Tc}$

One proceeds as for example 1. The RCP is 98%.

#### Example 6

##### Starch modification

One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq ( $0.1 \times 0.055 \times 2$ ), that is 0.011 mole of 4-methyl 3-thiosemicarbazide ( $\text{NH}_2\text{NH}(\text{C}=\text{S})\text{NH}(\text{CH}_3)$ ,  $M=105$ , that is 1.15 g dissolved in 10 ml of ethanol. The suspension is shaken for 18 hours at room temperature. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 2.9%, which corresponds to a coupling level of the 4-methyl 3-thiosemicarbazone of 7.3% (7.3 units thiosemicarbazide for 100 theoretical aldehyde functions, that is 14.6 thiosemicarbazone units for 100 units glucose). The coupling yield is thus 73%.

##### Labelling reaction with $^{99\text{m}}\text{Tc}$

One proceeds as for example 1. The RCP is 97%.

#### Example 7

##### Starch modification

One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq ( $0.1 \times 0.055 \times 2$ ), that is 0.011 mole of 4,4-dimethyl 3-thiosemicarbazide ( $\text{NH}_2\text{NH}(\text{C}=\text{S})\text{N}(\text{CH}_3)_2$ ,  $M=119$ , that is 1.30 g dissolved in 10 ml of ethanol. The suspension is

stirred for 18 hours at room temperature. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 3%, which corresponds to a coupling level of the 4,4-dimethyl 3-thiosemicarbazone of 7.5% (7.5 units thiosemicarbazide for 100 theoretical aldehyde functions, that is 15 thiosemicarbazone units for 100 units glucose). The coupling yield is thus 75%.

Labelling reaction with  $^{99m}\text{Tc}$

One proceeds as for example 1. The RCP is 96%.

Example 8

Starch modification

One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq ( $0.1 \times 0.055 \times 2$ ), that is 0.011 mole of 4-allyl 3-thiosemicarbazide ( $\text{NH}_2\text{NH}(\text{C}=\text{S})\text{NH}(\text{CH}_2\text{CH}=\text{CH}_2)$ ,  $M=131$ , that is 1.44 g dissolved in 10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 3%, which corresponds to a coupling level of the 4-allyl 3-thiosemicarbazone of 7.5% (7.5 units thiosemicarbazide for 100 theoretical aldehyde functions, that is 15 thiosemicarbazone units for 100 units glucose). The coupling yield is thus 75%.

Labelling reaction with  $^{99m}\text{Tc}$ 

One proceeds as for example 1. The RCP is 98%.

Example 9Starch modification

- 5 One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq ( $0.1 \times 0.055 \times 2$ ), that is 0.011 mole of 3-thiosemicarbazide ( $\text{NH}_2\text{NH}(\text{C}=\text{S})\text{NH}_2$ ,  $M=91$ , that is 1 g  
10 dissolved in 10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus  
15 obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 2.9%, which corresponds to a coupling level of the 3-thiosemicarbazone of 7.3% (7.3 units thiosemicarbazide for 100 theoretical aldehyde  
20 functions, that is 14.6 thiosemicarbazone units for 100 units glucose). The coupling yield is thus 73%.

Labelling reaction with  $^{99m}\text{Tc}$ 

One proceeds as for example 1. The RCP is 95%.

Example 10

25 Starch modification

- One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq  
30 ( $0.1 \times 0.055 \times 2$ ), that is 0.011 mole of 2-aminothiophenol ( $\text{C}_6\text{H}_4(\text{NH}_2)(\text{SH})$ ,  $M=125$ , that is 1.37 g dissolved in

10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus obtains  
5 about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 3%, which corresponds to a coupling level of the 2-aminothiophenol of 7.5% (7.5 units aminothiophenol for 100 theoretical aldehyde functions, that is 15  
10 aminothiophenol units for 100 units glucose). The coupling yield is thus 75%.

Labelling reaction with  $^{99m}\text{Tc}$

One proceeds as for example 1. The RCP is 94%.

Example 11

15 Starch modification

One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq  
20  $(0.1 \times 0.055 \times 2)$ , that is 0.011 mole of 2-mercaptoethylamine (or 2-aminoethanethiol)  $(\text{NH}_2\text{CH}_2\text{CH}_2\text{SH})$ ,  $M=91$ , that is 1 g dissolved in 10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. Next one adds 0.015 mole of sodium  
25 borohydride  $(\text{NaBH}_4)$  so as to reduce the Schiff base formed to stabilise it (non-aromatic Schiff bases not being stable) and leaves it to react for 1 hour. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried.  
30 One thus obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a



sulphur content of 3.4%, which corresponds to a coupling level of the 2-mercaptoethylamine of 8.5% (8.5 units 2-mercaptoethylamine for 100 theoretical aldehyde functions, that is 17 2-mercaptoethylamine units for 100 units glucose). The coupling yield is thus 85%.

Labelling reaction with  $^{99m}\text{Tc}$

One proceeds as for example 1. The RCP is 95%.

Example 12

Starch modification

10 One proceeds as for example 1 to obtain 10 g of starch oxidised at 30%. A suspension is prepared of 10 g of starch oxidised at 30% in 60 ml of a mixture of water/ethanol (2/1 by volume). Next one adds 0.1 eq (0.1x0.055x2), that is 0.011 mole of 2-amino 4-  
15 mercaptotriazole ( $\text{C}_4\text{N}_2\text{H}(\text{SH})(\text{NH}_2)$ ,  $M=116$ , that is 1.27 g dissolved in 10 ml of ethanol. The suspension is stirred for 18 hours at room temperature. The solution is then filtered and the modified starch washed by 3 times 20 ml ethanol and then vacuum dried. One thus  
20 obtains about 10 g of modified starch. The assay of the powder by elementary analysis gives a sulphur content of 2.8%, which corresponds to a coupling level of the 2-amino 4-mercaptotriazole of 7% (7 units mercaptotriazole for 100 theoretical aldehyde  
25 functions, that is 14 mercaptotriazole units for 100 units glucose). The coupling yield is thus 75%.

Labelling reaction with  $^{99m}\text{Tc}$

One proceeds as for example 1. The RCP is 85%.

Comparative example 1

30 One uses 10 g of sieved pharmacopoeia maize which has not undergone chemical transformation and one



carries out the same procedure as in example 1 to label it with  $^{99m}\text{Tc}$ .

The RCP is 19%.

This example is a good demonstration of the fact  
5 that the chemical modification (fixation of sequestering groups) carried out according to the invention is certainly necessary to allow labelling with  $^{99m}\text{Tc}$ . In addition, one cannot obtain durable pulmonary captation if the microparticles are labelled  
10 without prior chemical transformation contrary to the product relating to the present invention. These results are therefore in contradiction with that which is described in FR-A-2 273 516 (equivalent to GB 1 518 813).

#### Example 13

#### 15 Cellulose modification

One proceeds as in example 1 but using sieved cellulose between 10 and 40  $\mu\text{m}$ . Thus one obtains 10 g of cellulose oxidised at 30% and coupled to the DTCZ at 7%.

#### 20 Labelling reaction to $^{99m}\text{Tc}$

One proceeds as in example 1. The RCP is 99.1%.

#### Example 14

Sprague Dawley rats weighing about 200 g are anaesthetised with sodium thiopental, and are injected  
25 intravenously with different solutions of microspheres labelled with  $^{99m}\text{Tc}$  according to examples 1 to 9 and 13. Each animal receives 0.2 ml of solution in the penis vein, that is 0.2 mc per animal. The animals are then placed under a gamma-ray camera and successive static  
30 images are shot over a period of 3 hours. One thus obtains successive images after acquiring 15,000 shots

per image. Then, manually, one defines the zones of interest in order to estimate the activity present in the different organs 15 minutes after the injection. The results are given in tables I below.

5

Tables I: Results

% activity 15 min. after I.V.	Example 1	Example 2	Example 3	Example 4	Example 5
% pulmon. activity	90%	85%	80%	80%	85%
% hepat. activity	<5%	<5%	<5%	<10%	<10%
pulmon. half-life	2 hours	1 hour	30 mins	2 hours	2 hours

% activity 15 min. after I.V.	Example 6	Example 7	Example 8	Example 9	Example 10 Example 13
% pulmon. activity	85%	85%	85%	85%	90%
% hepat. activity	<5%	<5%	<5%	<5%	<5%
pulmon. half-life	2 hours	2 hours	2 hours	2 hours	> 4 hours

10

One thus notes that the modified microspheres show very good pulmonary captation. In addition, one can modulate the speed of pulmonary elimination by varying

INTELLECTUAL PROPERTY  
OFFICE OF N.Z.

28 22 MAR 2002

RECEIVED

the oxidation level as shown in examples 1, 2 and 3 (oxidation levels 30, 20 and 10%).

The usage of cellulose makes it possible to lengthen the speed of elimination considerably (example 5 10, half-life > 4 hours).

#### Comparative example 2

In this example, natural starch is not used, but microspheres prepared from amylopectin reticulated by epichlorhydrin as in the patent FR-A-2 273 516 (equivalent to GB 1 518 813).

#### 10 Preparation of reticulated microspheres of starch

One dissolves 8 g of maize amylopectin in 40 ml of a solution containing 4 g of NaOH and 0.15 g of sodium borohydride. The amylopectin is left for 24 hours to dissolve. Next one prepares an emulsion by stirring 15 60 ml of fluid paraffin and 1.6 g of soy lecithin dissolved in 4 ml of hexane at 800 revs/min. Then one adds the aqueous phase containing the amylopectin and then 3.2 ml of epichlorhydrin. The emulsion is heated to 55°C for 4 hours and then left to be stirred 20 overnight. The microspheres obtained of a size around 50 µm are washed by 3 times 250 ml of acetone, dried and then lyophilised.

#### Labelling with <sup>99m</sup>Tc

One proceeds as for example 1 but using 1 mg of 25 SnCl<sub>2</sub> · 2H<sub>2</sub>O. The RCP is 90%.

#### Starch modification

One proceeds as for example 1 but using 10 g of microspheres of amylopectin reticulated by the epichlorhydrin previously prepared. One thus obtains 10 g of microspheres of amylopectin oxidised at 30% and 30 coupled to the DTCZ at 7%.

Labelling reaction with  $^{99m}\text{Tc}$ 

One proceeds as for example 1. The RCP is 99%.

Example 15

- One follows the same operational mode as in  
5. example 14 to test the microspheres of reticulated amylo-  
pectin labelled with  $^{99m}\text{Tc}$  of the comparative example 2.  
The results obtained are given in table II below.

Table II

% activity 15 min. after I.V.	Comparative example 2 *	Example 17 **
% pulmonary activity	< 10%	85%
% hepatic activity	70%	< 5%
pulmonary half-life		2 hours

10

- One notes that contrary to the description in FR-A-2 273 516  
(equivalent to GB 1 518 813) the microspheres of reticulated  
amylopectin not modified chemically are labelled by  $^{99m}\text{Tc}$  but  
do not present any pulmonary captation, doubtless due to the  
15 weak link between  $^{99m}\text{Tc}$  and the microspheres. On the  
other hand, these microspheres transformed chemically  
by the procedure of the invention demonstrate good  
pulmonary captation.

Example 16

- 20 Starch microspheres prepared as in example 1  
(starch oxidised at 30%, coupled with DTCZ at 7%) are  
used to produce sterile labelling kits and are ready  
for labelling with  $^{99m}\text{Tc}$ .

Sterilisation of the microspheres

- 25 10 g of microspheres are introduced into a flask  
crimped and then irradiated by a source of cobalt-60.

\* Comparative example 2  
Part 2.1

\*\* Comparative example 2  
Part 2.2

The microspheres receive a total dose of gamma radiation of 25kGy over 20 hours.

Preparation of the kits

200 mg of sterilised microspheres are introduced in a sterile way into a reactor containing 20 ml of NaCl 9/1000. The solution is de-aerated by nitrogen bubbling and then one adds 400 µl of a sterile solution of  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  at 0.5 mg/ml in HCl 0.1N. One separates 1 ml of solution for each of 20 flasks, which are then lyophilised and placed in a nitrogen atmosphere.

Each flask thus contains:

10 mg of modified microspheres

10 µg of  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$

9 mg of NaCl

Labelling reaction with  $^{99\text{m}}\text{Tc}$

5 ml of  $\text{TcO}_4^-$  (5mc) solution is added to a flask in lyophilised form and left to react for 15 minutes.

One proceeds as in example 1. The RCP is 98.7%.

Kit stability trial

Labelling kits prepared as above are stored at different temperatures and then the labelling reaction to  $^{99\text{m}}\text{Tc}$  is tested so as to evaluate their stability. The results obtained are given in table III below:

Table III : RCP (%)

Storage temperature	6 months	12 months
2-8°C	98.5%	98.4%
25°C	97%	96%
45°C	94%	90%

One notes the very high stability of the kit stored at a temperature between 2 and 8°C.

**Example 17**

Sprague Dawley rats weighing about 200 g are anaesthetised with sodium thiopental, and are then injected intravenously with different solutions of microspheres labelled with  $^{99m}\text{Tc}$  as in example 14. Each animal receives 0.2 ml of solution in the penis vein, that is 0.2 mc per animal. The animals are then killed 15 minutes after the injection. Next, the different organs are retrieved, the measurement of radioactivity present in each organ is counted and thus the percentage of activity present in each organ is determined. The results are given in table IV below:

Table IV - Results

15      % of the dose injected 15 minutes after injection

Organs	Example 1	Example 13
Blood (1 ml)	0.1%	0.2%
Liver	2.2%	5.6%
Kidneys	0.4%	0.4%
Lungs	91%	82%
Spleen	0.1%	0.1%
Intestines	1.5%	0.7%
Bladder	0.1%	1.3%

One thus notes a very high pulmonary captation whereas as there is weak captation in the other organs for natural starch microspheres as well as reticulated starch base microspheres. The sterile product prepared under kit form thus seems completely adapted to usage as a radiopharmaceutical product for pulmonary perfusion substituting for albumin, and for radiotherapy.

**Example 18**

One uses cellulose oxidised at 30% and coupled with the DTCZ at 7% as in example 13. The cellulose thus modified is labelled with rhenium 186 in order to illustrate the utilisation of the support according to the present invention for therapy.

**Labelling reaction with Re 186**

10 mg of modified cellulose are introduced into a penicillin type flask. One then adds 2 ml of physiological serum and then 20 mg of citric acid and finally 1 mg of  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  (100  $\mu\text{l}$  of a solution at 10 mg/ml in  $\text{HCl}$  0.1 N).

Next one adds to the contents of the flask 0.1 ml of  $\text{ReO}_4^-$  solution corresponding to an activity of 2 mc. The flask is heated in a water bath at  $100^\circ\text{C}$  for 30 minutes. The radiochemical purity (RCP) is determined by filtration on a Millipore as in example 1.

RCP = 92%

In order to prove the stability of the link between rhenium 186 and the cellulose microspheres, a stability test in vitro is carried out.

The mixture is incubated with HSA (human serum albumin) at 20 mg/ml at  $37^\circ\text{C}$ . The following results are obtained:

Incubation time	0	2 hours	6 hours	24 hours	48 hours
RCP	92%	92%	91%	89%	90%

25 These results therefore prove the very high stability of labelling of cellulose microspheres with rhenium 186 and the high stability of the microspheres themselves vis-à-vis HSA.



The expert will easily understand that these results can be extrapolated to the utilisation of rhenium 188.

**Example 19**

5 Sprague Dawley rats weighing about 200 g are anaesthetised and then injected with 0.2 ml (0.1 mc) of cellulose microsphere solution labelled with Re 186 as in example 18.

10 The animals are then placed under a gamma-ray camera and images are registered over 48 hours.

The activity present in the zones of interest is then calculated as in example 14.

Time after injection	1 hour	2 hours	6 hours	24 hours	48 hours
% pulmon. activity	80%	85%	85%	85%	90%
% hepatic activity	<5%	<5%	<5%	<5%	<5%

15 These results therefore prove that the activity remains blocked at the pulmonary level for at least 48 hours. This type of microsphere can thus be used for therapy.

20 The most important clinical application can be the treatment of liver cancers after injection, not intravenously but directly into the hepatic artery (metabolic radiotherapy).

25 Another possible application is to inject this type of particle subcutaneously in breast cancer. The particles migrating through the lymphatic system may

make it possible to treat the sentinel nodes invaded by cancerous cells.

Printed 26-10-01


CLMS

009517841B00031

35

CLAIMS


1. A radiopharmaceutical product comprising a polysaccharide provided with sequestering groups linked to the polysaccharide by covalent bonds and chosen from among the groups of formulae R-NH-, R-N=, and



- in which R is a hydrocarbonic or aromatic group comprising at least one atom of sulphur, and R' is an atom of hydrogen or an alkyl, said sequestering groups forming, together with a radioactive metal chosen from among technetium, rhenium, copper, yttrium, erbium, gallium and samarium, a complex of the chelate type, in which the polysaccharide is in the form of microparticles.

2. A radiopharmaceutical product according to claim 1 wherein R' is methyl.

3. A radiopharmaceutical product according to claim 1 in which the sequestering groups are chosen from among the groups of formulae:



IPONZ


- 2 JUL 2003

in which  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are independently atoms of hydrogen atoms, saturated or unsaturated hydrocarbonic groups, carboxylic groups or aromatic groups,

(A)


- 5 is an aromatic nucleus possibly containing one or several heteroatoms, and  $n$  is a whole number between 1 and 5.

4. A radiopharmaceutical product according to  
10 Claim 3 in which the sequestering groups are chosen from among the groups of formulae:



15

IPONZ  
- 2 JUL 2003



5. A radiopharmaceutical product according to any one of Claims 1 to 4, in which the polysaccharide is chosen from among natural starch, cellulose and reticulated amylopectin.

6. A radiopharmaceutical product according to any one of Claims 1 to 5, in which the microparticles have a diameter between 0.01 and 100  $\mu\text{m}$ .

10

7. A radiopharmaceutical product according to any one of Claims 1 to 6, in which the level of

IPONZ

- 2 JUL 2003

sequestering groups is from 0.1 to 50% relative to the saccharide units of polysaccharide.

8. A radiopharmaceutical product according to any one of claims 1 to 7, in the form of a suspension of microspheres in a physiologically acceptable liquid or in lyophilised form.

9. Utilisation of a radiopharmaceutical product according to any one of Claims 1 to 7, in which the radioactive metal is <sup>99m</sup>Tc or <sup>67</sup>Ga to prepare a product intended for diagnosis.

10. Utilisation of a radiopharmaceutical product according to any one of Claims 1 to 7, in which the radioactive metal is rhenium-186 or 188, copper-64 or 67, yttrium 90, erbium 169 or samarium 153, to prepare a drug.


11. Utilisation of a radiopharmaceutical product according to any one of Claims 1 to 7, in which the radioactive metal is <sup>99m</sup>Tc to prepare a product intended for pulmonary scintigraphy.

12. A procedure for preparation of a radiopharmaceutical product according to any one of Claims 1 to 7, which comprises the following stages:  
(a) submit a polysaccharide to an oxidation carried out by means of a periodate.

IPONZ

- 2 JUL 2003

(b) make the oxidated polysaccharide react with a compound containing a primary amine function or hydrazin of formula  $R-NH_2$  or



5

in which R is a hydrocarbonic or aromatic group comprising at least one atom of sulphur, in order to bond in a covalent manner to the polysaccharide with metal sequestering groups of formulae  $R-NH-$ ,  $R-N=$  or  $R-NH-N=$ , and R' is a hydrogen atom or an alkyl,

10

(c) make the polysaccharide comprising the sequestering groups react with a salt of a radioactive metal chosen from among technetium, rhenium, copper, yttrium, erbium and samarium.

15

13. A procedure according to claim 11 wherein R' is methyl.

20


14. A procedure according to claim 12, in which the compound containing a primary amine function corresponds to the formula  $NH_2-(CH_2)_n-SH$  with n being a whole number from 1 to 5, and comprising a supplementary stage of reduction of this compound by sodium borohydride between stages (b) and (c).

25

15. A procedure according to Claim 12, in which the compound bonded to the oxidised polysaccharide corresponds to one of the following formulae:

IPONZ

- 2 JUL 2003



16. A procedure according to any one of Claims 12  
 5 to 15, in which the level of sequestering groups fixed  
 on the polysaccharide is regulated by controlling the  
 level of oxidation of the polysaccharide in stage (a).

17. A procedure according to Claim 16, in which  
 10 the oxidation level of the polysaccharide is from 10 to  
 50%.

18. A procedure according to Claim 16, in which  
 the level of sequestering groups is from 2 to 15%.

IPONZ


- 2 JUL 2003



19. A procedure according to any one of Claims 12 to 18, in which the stage (c) consists of putting into contact microspheres of polysaccharide comprising sequestering groups with a solution of pertechnetate  $^{99m}\text{TcO}_4^-$ , in the presence of a reducing agent.

20. A diagnosis kit which can be used for pulmonary scintigraphy which comprises:

10 a first flask containing a polysaccharide provided with sequestering groups linked to said polysaccharide by covalent bonds and chosen among the formulae groups R-NH-, R-N= and



15

in which R is a hydrocarbonic or aromatic group comprising at least one atom of sulphur, and in which R' is an atom of hydrogen or an alkyl, in which the polysaccharide is in the form of lyophilised microparticles or in suspension in a pharmaceutically acceptable liquid.

20

21. A diagnosis kit according to claim 20 wherein R' is methyl.

25

22. A kit according to claim 20 comprising also a second flask containing stannous chloride in lyophilised form.

23. A kit according to claim 20, in which the polysaccharide being in the form of lyophilised

IPONZ

- 2 JUL 2003

microparticles in the first flask, said first flask also contains lyophilised stannous chloride.

IPONZ

- 2 JUL 2003

24. A radiopharmaceutical product according to claim 1 substantially as herein described or exemplified.

25. A utilisation according to claim 9 substantially as herein described or exemplified.

26. A utilisation according to claim 10 substantially as herein described or exemplified.

27. A utilisation according to claim 11 substantially as herein described or exemplified.

28. A procedure according to claim 12 substantially as herein described or exemplified.

29. A diagnosis kit according to claim 20 substantially as herein described or exemplified.

**IPONZ**

**- 2 JUL 2003**

---

**END**

---

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**